Latent membrane protein 2 (LMP2)

Current Topics in Microbiology and Immunology

Volumn 391, Issue , 2015, Pages 151-180

  Cen, Osman ^a   Longnecker, Richard ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; FOSTAMATINIB; ISOPROTEIN; ITAM PROTEIN; LATENT MEMBRANE PROTEIN 2; LMP2A PROTEIN; LMP2B PROTEIN; MEMBRANE PROTEIN; PHOSPHOTRANSFERASE; PROTEIN KINASE SYK INHIBITOR; PROTEIN SH2; RAPAMYCIN; TAK 659; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; EBV-ASSOCIATED MEMBRANE ANTIGEN, EPSTEIN-BARR VIRUS; MATRIX PROTEIN;

AMINO TERMINAL SEQUENCE; B LYMPHOCYTE ACTIVATION; CARBOXY TERMINAL SEQUENCE; CELL COMMUNICATION; DIMERIZATION; DOWN REGULATION; DRUG TARGETING; ENZYME DEGRADATION; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE STRUCTURE; HETERODIMERIZATION; HOMODIMERIZATION; HUMAN; LMP2 GENE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; ANIMAL; B LYMPHOCYTE; CHEMISTRY; EPSTEIN BARR VIRUS INFECTION; GENETICS; METABOLISM; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

ANIMALS; B-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; VIRAL MATRIX PROTEINS;

EID: 84943271330     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/978-3-319-22834-1_5     Document Type: Chapter

References (129)

1. Allen MD, Young LS, Dawson CW (2005) The Epstein-Barr virus-encoded LMP2A and LMP2B proteins promote epithelial cell spreading and motility. J Virol 79(3):1789-1802. doi:10.112 8/jvi.79.3.1789-1802.2005
2. Alvarado JJ, Tarafdar S, Yeh JI, Smithgall TE (2014) Interaction with the SH3-SH2 region of the Src-family kinase Hck structures the HIV-1 Nef dimer for kinase activation and effector recruitment. J Biol Chem. doi:10.1074/jbc.M114.600031
3. Anderson LJ, Longnecker R (2008a) EBV LMP2A provides a surrogate pre-B cell receptor signal through constitutive activation of the ERK/MAPK pathway. J Gen Virol 89(7):1563-1568. doi:10.1099/vir.0.2008/001461-0 [pii] 89/7/1563
4. Anderson LJ, Longnecker R (2008b) An auto-regulatory loop for EBV LMP2A involves activation of notch. Virology 371(2):257-266. doi:10.1016/j.virol.2007.10.009 [pii] S0042-6822(07)00666-6
5. Anderson LJ, Longnecker R (2009) Epstein-Barr virus latent membrane protein 2A exploits Notch1 to alter B-cell identity in vivo. Blood 113(1):108-116. doi:10.1182/blood-2008-06-160937 [pii] blood-2008-06-160937
6. Babcock GJ, Thorley-Lawson DA (2000) Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci USA 97(22):12250-12255. doi:10.1073/pnas.200366597
7. Babcock GJ, Hochberg D, Thorley-Lawson AD (2000) The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13(4):497-506
8. Beaufils P, Choquet D, Mamoun RZ, Malissen B (1993) The (YXXL/I)2 signalling motif found in the cytoplasmic segments of the bovine leukaemia virus envelope protein and Epstein-Barr virus latent membrane protein 2A can elicit early and late lymphocyte activation events. EMBO J 12(13):5105-5112
9. Bell AI, Groves K, Kelly GL, Croom-Carter D, Hui E, Chan AT, Rickinson AB (2006) Analysis of Epstein-Barr virus latent gene expression in endemic Burkitt's lymphoma and nasopharyngeal carcinoma tumour cells by using quantitative real-time PCR assays. J Gen Virol 87(10):2885-2890. doi:10.1099/vir.0.81906-0 [pii] 87/10/2885
10. Bieging KT, Amick AC, Longnecker R (2009) Epstein-Barr virus LMP2A bypasses p53 inactivation in a MYC model of lymphomagenesis. Proc Natl Acad Sci USA 106(42):17945-17950. doi:10.1073/pnas.0907994106 [pii] 0907994106
11. Bieging KT, Fish K, Bondada S, Longnecker R (2011) A shared gene expression signature in mouse models of EBV-associated and non-EBV-associated Burkitt lymphoma. Blood 118(26):6849-6859. doi:10.1182/blood-2011-02-338434 [pii] blood-2011-02-338434
12. Booden MA, Baker TL, Solski PA, Der CJ, Punke SG, Buss JE (1999) A non-farnesylated Ha-Ras protein can be palmitoylated and trigger potent differentiation and transformation. J Biol Chem 274(3):1423-1431
13. Buhl AM, Cambier JC (1997) Co-receptor and accessory regulation of B-cell antigen receptor signal transduction. Immunol Rev 160:127-138
14. Bultema R, Longnecker R, Swanson-Mungerson M (2009) Epstein-Barr virus LMP2A accelerates MYC-induced lymphomagenesis. Oncogene 28(11):1471-1476. doi:10.1038/ onc.2008.492 [pii] onc2008492
15. Burkhardt AL, Bolen JB, Kieff E, Longnecker R (1992) An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases. J Virol 66(8):5161-5167
16. Cadwallader KA, Paterson H, Macdonald SG, Hancock JF (1994) N-terminally myristoylated Ras proteins require palmitoylation or a polybasic domain for plasma membrane localization. Mol Cell Biol 14(7):4722-4730
17. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R (1998) Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9(3):405-411 [pii] S1074-7613(00)80623-8
18. Caldwell RG, Brown RC, Longnecker R (2000) Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 74(3):1101-1113
19. Cambier JC, Bedzyk W, Campbell K, Chien N, Friedrich J, Harwood A, Jensen W, Pleiman C, Clark MR (1993) The B-cell antigen receptor: structure and function of primary, secondary, tertiary and quaternary components. Immunol Rev 132:85-106
20. Casola S, Otipoby KL, Alimzhanov M, Humme S, Uyttersprot N, Kutok JL, Carroll MC, Rajewsky K (2004) B cell receptor signal strength determines B cell fate. Nat Immunol 5(3):317-327. doi:10.1038/ni1036
21. Cen O, Longnecker R (2011) Rapamycin reverses splenomegaly and inhibits tumor development in a transgenic model of Epstein-Barr virus-related Burkitt's lymphoma. Mol Cancer Ther 10(4):679-686. doi:10.1158/1535-7163.MCT-10-0833 [pii] 1535-7163.MCT-10-0833
22. Cen O, Gorska MM, Stafford SJ, Sur S, Alam R (2003) Identification of UNC119 as a novel activator of SRC-type tyrosine kinases. J Biol Chem 278(10):8837-8845. doi:10.1074/jbc. M208261200 [pii] M208261200
23. Chen SY, Lu J, Shih YC, Tsai CH (2002) Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J Virol 76(18):9556-9561
24. Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL (2011) SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 118(24):6342-6352. doi:10.1182/blood-2011-02-333773 [pii] blood-2011-02-333773
25. Concha M, Wang X, Cao S, Baddoo M, Fewell C, Lin Z, Hulme W, Hedges D, McBride J, Flemington EK (2012) Identification of new viral genes and transcript isoforms during Epstein-Barr virus reactivation using RNA-Seq. J Virol 86(3):1458-1467. doi:10.1128/ jvi.06537-11
26. Cuiffo B, Ren R (2010) Palmitoylation of oncogenic NRAS is essential for leukemogenesis. Blood 115(17):3598-3605. doi:10.1182/blood-2009-03-213876
27. DalPorto JM, Gauld SB, Merrell KT, Mills D, Pugh-Bernard AE, Cambier J (2004) B cell antigen receptor signaling 101. Mol Immunol 41(6-7):599-613. doi:10.1016/j.molimm.2004.04.008
28. Dargart JL, Fish K, Gordon LI, Longnecker R, Cen O (2012) Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A. Antiviral Res. doi:10.1016/j. antiviral.2012.05.003
29. Dergai O, Dergai M, Skrypkina I, Matskova L, Tsyba L, Gudkova D, Rynditch A (2013) The LMP2A protein of Epstein-Barr virus regulates phosphorylation of ITSN1 and Shb adaptors by tyrosine kinases. Cell Signal 25(1):33-40. doi:10.1016/j.cellsig.2012.09.011
30. Dykstra ML, Longnecker R, Pierce SK (2001) Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 14(1):57-67 [pii] S1074-7613(01)00089-9
31. Engels N, Merchant M, Pappu R, Chan AC, Longnecker R, Wienands J (2001) Epstein-Barr virus latent membrane protein 2A (LMP2A) employs the SLP-65 signaling module. J Exp Med 194(3):255-264
32. Engels N, Yigit G, Emmerich CH, Czesnik D, Schild D, Wienands J (2012) Epstein-Barr virus LMP2A signaling in statu nascendi mimics a B cell antigen receptor-like activation signal. Cell commun signal CCS 10:9. doi:10.1186/1478-811x-10-9
33. Fish K, Chen J, Longnecker R (2014) Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood 123(4):530-540. doi:10.1182/blood-2013-07-517649
34. Fotheringham JA, Raab-Traub N (2013) Epstein-Barr virus latent membrane protein 2 effects on epithelial acinus development reveal distinct requirements for the PY and YEEA motifs. J Virol 87(24):13803-13815. doi:10.1128/jvi.02203-13
35. Fotheringham JA, Coalson NE, Raab-Traub N (2012) Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk-and Akt-dependent epithelial migration through alphav-integrin membrane translocation. J Virol 86(19):10308-10320. doi:10.1128/jvi.00853-12
36. Fox CP, Haigh TA, Taylor GS, Long HM, Lee SP, Shannon-Lowe C, O'Connor S, Bollard CM, Iqbal J, Chan WC, Rickinson AB, Bell AI, Rowe M (2010) A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK-and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy. Blood 116(19):3695-3704. doi:10.1182/ blood-2010-06-292268
37. Fruehling S, Longnecker R (1997) The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 235(2):241-251. doi:10.1006/viro.1997.8690 [pii] S0042-6822(97)98690-6
38. Fruehling S, Lee SK, Herrold R, Frech B, Laux G, Kremmer E, Grasser FA, Longnecker R (1996) Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction. J Virol 70(9):6216-6226
39. Fruehling S, Swart R, Dolwick KM, Kremmer E, Longnecker R (1998) Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol 72(10):7796-7806
40. Fukuda M, Kawaguchi Y (2014) Role of the immunoreceptor tyrosine-based activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-induced cell transformation. J Virol 88(9):5189-5194. doi:10.1128/jvi.03714-13
41. Fukuda M, Longnecker R (2005) Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation. J Virol 79(13):8655-8660. doi:10.1128/JVI.79.13.8655-8660.2005 [pii] 79/13/8655
42. Han J, Chen JN, Zhang ZG, Li HG, Ding YG, Du H, Shao CK (2012) Sequence variations of latent membrane protein 2A in Epstein-Barr virus-associated gastric carcinomas from Guangzhou, southern China. PLoS One 7(3):e34276. doi:10.1371/journal.pone.0034276
43. Harwood NE, Batista FD (2010) Early events in B cell activation. Annu Rev Immunol 28:185-210. doi:10.1146/annurev-immunol-030409-101216
44. Hatton O, Lambert SL, Phillips LK, Vaysberg M, Natkunam Y, Esquivel CO, Krams SM, Martinez OM (2013) Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am J Transplant 13(4):883-890. doi:10.1111/ajt.12137
45. Higuchi M, Izumi KM, Kieff E (2001) Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors. Proc Natl Acad Sci USA 98(8):4675-4680. doi:10.1073/p nas.081075298
46. Hislop AD, Taylor GS, Sauce D, Rickinson AB (2007) Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 25:587-617. doi:10.1146/ann urev.immunol.25.022106.141553
47. Hsiao FC, Lin M, Tai A, Chen G, Huber BT (2006) Cutting edge: Epstein-Barr virus transactivates the HERV-K18 superantigen by docking to the human complement receptor 2 (CD21) on primary B cells. J Immunol 177(4):2056-2060
48. Hsiao FC, Tai AK, Deglon A, Sutkowski N, Longnecker R, Huber BT (2009) EBV LMP-2A employs a novel mechanism to transactivate the HERV-K18 superantigen through its ITAM. Virology 385(1):261-266. doi:10.1016/j.virol.2008.11.025 [pii] S0042-6822(08)00766-6
49. Ikeda M, Longnecker R (2009) The c-Cbl proto-oncoprotein downregulates EBV LMP2A signaling. Virology 385(1):183-191. doi:10.1016/j.virol.2008.11.018 [pii] S0042-6822(08)00758-7
50. Ikeda M, Ikeda A, Longan LC, Longnecker R (2000) The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology 268(1):178-191. doi:10.1006/viro.1999.0166 [pii] S0042-6822(99)90166-6
51. Ikeda M, Ikeda A, Longnecker R (2001) PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins. J Virol 75(12):5711-5718. doi:10.1128/JVI.75.12.5711-5718.2001
52. Ikeda M, Ikeda A, Longnecker R (2002) Lysine-independent ubiquitination of Epstein-Barr virus LMP2A. Virology 300(1):153-159 [pii] S004268220291562X
53. Ikeda A, Caldwell RG, Longnecker R, Ikeda M (2003) Itchy, a Nedd4 ubiquitin ligase, downregulates latent membrane protein 2A activity in B-cell signaling. J Virol 77(9):5529-5534
54. Ikeda A, Merchant M, Lev L, Longnecker R, Ikeda M (2004) Latent membrane protein 2A, a viral B cell receptor homologue, induces CD5 + B-1 cell development. J Immunol 172(9):5329-5337
55. Ingham RJ, Colwill K, Howard C, Dettwiler S, Lim CS, Yu J, Hersi K, Raaijmakers J, Gish G, Mbamalu G, Taylor L, Yeung B, Vassilovski G, Amin M, Chen F, Matskova L, Winberg G, Ernberg I, Linding R, O'Donnell P, Starostine A, Keller W, Metalnikov P, Stark C, Pawson T (2005a) WW domains provide a platform for the assembly of multiprotein networks. Mol Cell Biol 25(16):7092-7106. doi:10.1128/MCB.25.16.7092-7106.2005 [pii] 25/16/7092
56. Ingham RJ, Raaijmakers J, Lim CS, Mbamalu G, Gish G, Chen F, Matskova L, Ernberg I, Winberg G, Pawson T (2005b) The Epstein-Barr virus protein, latent membrane protein 2A, co-opts tyrosine kinases used by the T cell receptor. J Biol Chem 280(40):34133-34142. doi:10.1074/jbc.M507831200 [pii] M507831200
57. Katzman RB, Longnecker R (2004) LMP2A does not require palmitoylation to localize to buoyant complexes or for function. J Virol 78(20):10878-10887. doi:10.1128/ JVI.78.20.10878-10887.2004 [pii] 78/20/10878
58. Kong QL, Hu LJ, Cao JY, Huang YJ, Xu LH, Liang Y, Xiong D, Guan S, Guo BH, Mai HQ, Chen QY, Zhang X, Li MZ, Shao JY, Qian CN, Xia YF, Song LB, Zeng YX, Zeng MS (2010) Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathog 6(6):e1000940. doi:10.1371/journal.ppat.1000940
59. Laux G, Perricaudet M, Farrell PJ (1988) A spliced Epstein-Barr virus gene expressed in immortalized lymphocytes is created by circularization of the linear viral genome. EMBO J 7(3):769-774
60. Laux G, Economou A, Farrell PJ (1989) The terminal protein gene 2 of Epstein-Barr virus is transcribed from a bidirectional latent promoter region. J Gen Virol 70(Pt 11):3079-3084
61. Laux G, Adam B, Strobl LJ, Moreau-Gachelin F (1994a) The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J 13(23):5624-5632
62. Laux G, Dugrillon F, Eckert C, Adam B, Zimber-Strobl U, Bornkamm GW (1994b) Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol 68(11):6947-6958
63. Longnecker R, Druker B, Roberts TM, Kieff E (1991) An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase. J-Virol 65(7):3681-3692
64. Longnecker R, Merchant M, Brown ME, Fruehling S, Bickford JO, Ikeda M, Harty RN (2000) WW-and SH3-domain interactions with Epstein-Barr virus LMP2A. Exp Cell Res 257(2):332-340. doi:10.1006/excr.2000.4900 [pii] S0014-4827(00)94900-0
65. Longnecker R, Kieff E, Cohen JI (2013) Epstein-Barr virus replication. In: Knipe DM, Howley PT (eds) Fields virology, vol II, 6th edn. Lippincott Williams & Wilkins, Philadelphia
66. Lu J, Lin WH, Chen SY, Longnecker R, Tsai SC, Chen CL, Tsai CH (2006) Syk tyrosine kinase mediates Epstein-Barr virus latent membrane protein 2A-induced cell migration in epithelial cells. J Biol Chem 281(13):8806-8814. doi:10.1074/jbc.M507305200 [pii] M507305200
67. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, Chan AW, Ng EK, Lo KW, To KF (2009) Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia (New York, NY) 11(11):1174-1184
68. Luo B, Wang Y, Wang XF, Liang H, Yan LP, Huang BH, Zhao P (2005) Expression of Epstein-Barr virus genes in EBV-associated gastric carcinomas. World J Gastroenterol WJG 11(5):629-633
69. Lynch DT, Zimmerman JS, Rowe DT (2002) Epstein-Barr virus latent membrane protein 2B (LMP2B) co-localizes with LMP2A in perinuclear regions in transiently transfected cells. J Gen Virol 83(Pt 5):1025-1035
70. Mancao C, Altmann M, Jungnickel B, Hammerschmidt W (2005) Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106(13):4339-4344. doi:10.1182/blood-2005-06-2341
71. Matskova L, Ernberg I, Pawson T, Winberg G (2001) C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal. J Virol 75(22):10941-10949. doi:10.1128/JVI.75.22.10941-10949.2001
72. Matskova LV, Helmstetter C, Ingham RJ, Gish G, Lindholm CK, Ernberg I, Pawson T, Winberg G (2007) The Shb signalling scaffold binds to and regulates constitutive signals from the Epstein-Barr virus LMP2A membrane protein. Oncogene 26(34):4908-4917. doi:10.1038/sj.onc.1210298 [pii] 1210298
73. Merchant M, Longnecker R (2001) LMP2A survival and developmental signals are transmitted through Btk-dependent and Btk-independent pathways. Virology 291(1):46-54. doi:10.1006 /viro.2001.1187 [pii] S0042-6822(01)91187-0
74. Merchant M, Caldwell RG, Longnecker R (2000) The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 74(19):9115-9124
75. Meyn MA 3rd, Wilson MB, Abdi FA, Fahey N, Schiavone AP, Wu J, Hochrein JM, Engen JR, Smithgall TE (2006) Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity. J Biol Chem 281(41):30907-30916. doi:10.1074/jbc.M605902200
76. Miller CL, Longnecker R, Kieff E (1993) Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes. J Virol 67:3087-3094
77. Miller CL, Lee JH, Kieff E, Burkhardt AL, Bolen JB, Longnecker R (1994a) Epstein-Barr virus protein LMP2A regulates reactivation from latency by negatively regulating tyrosine kinases involved in sIg-mediated signal transduction. Infect Agents Dis 3(2-3):128-136
78. Miller CL, Lee JH, Kieff E, Longnecker R (1994b) An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 91(2):772-776
79. Miller CL, Burkhardt AL, Lee JH, Stealey B, Longnecker R, Bolen JB, Kieff E (1995) Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 2(2):155-166 [pii] S1074-7613(95)80040-9
80. Moarefi I, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, Miller WT (1997) Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385(6617):650-653. doi:10.1038/385650a0
81. Moody CA, Scott RS, Amirghahari N, Nathan CO, Young LS, Dawson CW, Sixbey JW (2005) Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. J Virol 79(9):5499-5506. doi:10.1128/JVI.79.9.5499-5506.2005 [pii] 79/9/5499
82. Morrison JA, Raab-Traub N (2005) Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 79(4):2375-2382. doi:10.1128/ JVI.79.4.2375-2382.2005 [pii] 79/4/2375
83. Morrison JA, Klingelhutz AJ, Raab-Traub N (2003) Epstein-Barr virus latent membrane protein 2A activates beta-catenin signaling in epithelial cells. J Virol 77(22):12276-12284
84. Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, Okada M, Aizawa S (1993) Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 73(6):1125-1135
85. Nakaya T, Kikuchi Y, Kunita A, Ishikawa S, Matsusaka K, Hino R, Aburatani H, Fukayama M (2013) Enrichment of stem-like cell population comprises transformation ability of Epstein-Barr virus latent membrane protein 2A for non-transformed cells. Virus Res 174(1-2):108-115. doi:10.1016/j.virusres.2013.03.009
86. Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, Lim WA (1998) Exploiting the basis of proline recognition by SH3 and WW domains: design of N-substituted inhibitors. Science 282(5396):2088-2092
87. Nomura K, Kanemura H, Satoh T, Kataoka T (2004) Identification of a novel domain of Ras and Rap1 that directs their differential subcellular localizations. J Biol Chem 279(21):22664-22673. doi:10.1074/jbc.M314169200
88. Ocheni SOD, Oyekunle AA (2010) EBV-associated malignancies. Open Infect Dis J 4(1):101-122
89. Okada M (2012) Regulation of the SRC family kinases by Csk. Int J Biol Sci 8(10):1385-1397. doi:10.7150/ijbs.5141
90. Pan YR, Vatsyayan J, Chang YS, Chang HY (2008) Epstein-Barr virus latent membrane protein 2A upregulates UDP-glucose dehydrogenase gene expression via ERK and PI3 K/Akt pathway. Cell Microbiol 10(12):2447-2460. doi:10.1111/j.1462-5822.2008.01221.x [pii] CMI1221
91. Panousis CG, Rowe DT (1997) Epstein-Barr virus latent membrane protein 2 associates with and is a substrate for mitogen-activated protein kinase. J Virol 71(6):4752-4760
92. Pegtel DM, Middeldorp J, Thorley-Lawson DA (2004) Epstein-Barr virus infection in ex vivo tonsil epithelial cell cultures of asymptomatic carriers. J Virol 78(22):12613-12624. doi:10. 1128/JVI.78.22.12613-12624.2004 [pii] 78/22/12613
93. Pegtel DM, Subramanian A, Sheen TS, Tsai CH, Golub TR, Thorley-Lawson DA (2005) Epstein-Barr-virus-encoded LMP2A induces primary epithelial cell migration and invasion: possible role in nasopharyngeal carcinoma metastasis. J Virol 79(24):15430-15442. doi:10.1128/ jvi.79.24.15430-15442.2005
94. Porfiri E, Evans T, Chardin P, Hancock JF (1994) Prenylation of Ras proteins is required for efficient hSOS1-promoted guanine nucleotide exchange. J Biol Chem 269(36):22672-22677
95. Portis T, Longnecker R (2003) Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J Virol 77(1):105-114
96. Portis T, Longnecker R (2004a) Epstein-Barr virus (EBV) LMP2A alters normal transcriptional regulation following B-cell receptor activation. Virology 318(2):524-533. doi:10.1016/ j.virol.2003.09.017 [pii] S0042682203007049
97. Portis T, Longnecker R (2004b) Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3 K/Akt pathway. Oncogene 23(53):8619-8628. doi:10.1038/sj.onc.1207905 [pii] 1207905
98. Portis T, Cooper L, Dennis P, Longnecker R (2002) The LMP2A signalosome-a therapeutic target for Epstein-Barr virus latency and associated disease. Front Biosci 7:d414-d426
99. Portis T, Dyck P, Longnecker R (2003) Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102(12):4166-4178. doi:10.1182/blood-2003-04-1018 [pii] 2003-04-1018
100. Qu L, Green M, Webber S, Reyes J, Ellis D, Rowe D (2000) Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J Infect Dis 182(4):1013-1021. doi:10.1086/315828
101. Rechsteiner MP, Berger C, Weber M, Sigrist JA, Nadal D, Bernasconi M (2007) Silencing of latent membrane protein 2B reduces susceptibility to activation of lytic Epstein-Barr virus in Burkitt's lymphoma Akata cells. J Gen Virol 88(Pt 5):1454-1459. doi:10.1099/vir.0.82790-0
102. Rechsteiner MP, Berger C, Zauner L, Sigrist JA, Weber M, Longnecker R, Bernasconi M, Nadal D (2008a) Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol 82(4):1739-1747. doi:10.1128/JVI.01723-07 [pii] JVI.01723-07
103. Rechsteiner MP, Bernasconi M, Berger C, Nadal D (2008b) Role of latent membrane protein 2 isoforms in Epstein-Barr virus latency. Trends Microbiol 16(11):520-527. doi:10.1016/j. tim.2008.08.007
104. Reth M (1989) Antigen receptor tail clue. Nature 338(6214):383-384. doi:10.1038/338383b0
105. Rovedo M, Longnecker R (2007) Epstein-barr virus latent membrane protein 2B (LMP2B) modulates LMP2A activity. J Virol 81(1):84-94. doi:10.1128/JVI.01302-06 [pii] JVI.01302-06
106. Rovedo M, Longnecker R (2008) Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. J Virol 82(17):8520-8528. doi:10.1128/ JVI.00843-08 [pii] JVI.00843-08
107. Rowe DT, Hall L, Joab I, Laux G (1990) Identification of the Epstein-Barr virus terminal protein gene products in latently infected lymphocytes. J Virol 64(6):2866-2875
108. Sample J, Liebowitz D, Kieff E (1989) Two related Epstein-Barr virus membrane proteins are encoded by separate genes. J Virol 63(2):933-937
109. Schaadt E, Baier B, Mautner J, Bornkamm GW, Adler B (2005) Epstein-Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation. J Gen Virol 86(Pt 3):551-559. doi:10.1099/vir.0.80440-0
110. Scholle F, Longnecker R, Raab-Traub N (1999) Epithelial cell adhesion to extracellular matrix proteins induces tyrosine phosphorylation of the Epstein-Barr virus latent membrane protein 2: a role for C-terminal Src kinase. J Virol 73(6):4767-4775
111. Scholle F, Bendt KM, Raab-Traub N (2000) Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 74(22):10681-10689
112. Scholle F, Longnecker R, Raab-Traub N (2001) Analysis of the phosphorylation status of Epstein-Barr virus LMP2A in epithelial cells. Virology 291(2):208-214. doi:10.1006/v iro.2001.1197 [pii] S0042-6822(01)91197-3
113. Shair KH, Raab-Traub N (2012) Transcriptome changes induced by Epstein-Barr virus LMP1 and LMP2A in transgenic lymphocytes and lymphoma. mBio 3 (5):e00288-12. doi:10.1128 /mBio.00288-12
114. Shishido T, Akagi T, Chalmers A, Maeda M, Terada T, Georgescu MM, Hanafusa H (2001) Crk family adaptor proteins trans-activate c-Abl kinase. Genes to Cells 6(5):431-440 [pii] gtc431
115. Sicheri F, Moarefi I, Kuriyan J (1997) Crystal structure of the Src family tyrosine kinase Hck. Nature 385(6617):602-609. doi:10.1038/385602a0
116. Stewart S, Dawson CW, Takada K, Curnow J, Moody CA, Sixbey JW, Young LS (2004) Epstein-Barr virus-encoded LMP2A regulates viral and cellular gene expression by modulation of the NF-kappaB transcription factor pathway. Proc Natl Acad Sci USA 101(44):15730-15735. doi:10.1073/pnas.0402135101
117. Strobl LJ, Hofelmayr H, Marschall G, Brielmeier M, Bornkamm GW, Zimber-Strobl U (2000) Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2. J Virol 74(4):1727-1735
118. Swanson-Mungerson M, Bultema R, Longnecker R (2006) Epstein-Barr virus LMP2A enhances B-cell responses in vivo and in vitro. J Virol 80(14):6764-6770. doi:10.1128/JVI.00433-06 [pii] 80/14/6764
119. Swart R, Ruf IK, Sample J, Longnecker R (2000) Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-Kinase/Akt pathway. J Virol 74(22):10838-10845
120. Tanaka M, Kawaguchi Y, Yokofujita J, Takagi M, Eishi Y, Hirai K (1999) Sequence variations of Epstein-Barr virus LMP2A gene in gastric carcinoma in Japan. Virus Genes 19(2):103-111
121. Tao Q, Robertson KD, Manns A, Hildesheim A, Ambinder RF (1998) Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood 91(4):1373-1381
122. Tomaszewski-Flick MJ, Rowe DT (2007) Minimal protein domain requirements for the intracellular localization and self-aggregation of Epstein-Barr virus latent membrane protein 2. Virus Genes 35(2):225-234. doi:10.1007/s11262-007-0118-8
123. Vockerodt M, Wei W, Nagy E, Prouzova Z, Schrader A, Kube D, Rowe M, Woodman CB, Murray PG (2013) Suppression of the LMP2A target gene, EGR-1, protects Hodgkin's lymphoma cells from entry to the EBV lytic cycle. J Pathol 230(4):399-409. doi:10.1002/ path.4198
124. Winberg G, Matskova L, Chen F, Plant P, Rotin D, Gish G, Ingham R, Ernberg I, Pawson T (2000) Latent membrane protein 2A of Epstein-Barr virus binds WW domain E3 proteinubiquitin ligases that ubiquitinate B-cell tyrosine kinases. Mol Cell Biol 20(22):8526-8535
125. Xue SA, Labrecque LG, Lu QL, Ong SK, Lampert IA, Kazembe P, Molyneux E, Broadhead RL, Borgstein E, Griffin BE (2002) Promiscuous expression of Epstein-Barr virus genes in Burkitt's lymphoma from the central African country Malawi. Int J Cancer 99(5):635-643. doi:10.1002/ijc.10372
126. Yoshioka M, Ishiguro N, Ishiko H, Ma X, Kikuta H, Kobayashi K (2001) Heterogeneous, restricted patterns of Epstein-Barr virus (EBV) latent gene expression in patients with chronic active EBV infection. J Gen Virol 82(Pt 10):2385-2392
127. Young MA, Gonfloni S, Superti-Furga G, Roux B, Kuriyan J (2001) Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell 105(1):115-126
128. Zimber-Strobl U, Suentzenich KO, Laux G, Eick D, Cordier M, Calender A, Billaud M, Lenoir GM, Bornkamm GW (1991) Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene. J Virol 65(1):415-423
129. Zimber-Strobl U, Kremmer E, Grasser F, Marschall G, Laux G, Bornkamm GW (1993) The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J 12(1):167-175